11 September 2020
Sydney's iconic Sun-Herald City2Surf 2020 is on Sunday 18 October 2020, it’s the 50th anniversary and this year the event is virtual, so more people can join in!
Hand sanitiser, social distancing, isolation, working from home…It’s all part of our ’new normal’. For events, the ‘new normal’ means a virtual event. It’s the perfect excuse to get a few mates together, enjoy the day and run, jog or walk 14kms in your neighbourhood to your own beat.
How does the virtual event work?
- Once you've registered you’ll receive an email with a link to download the C2S app
- Anytime between 6am and 6pm* on Sunday 18 October 2020, just open the C2S app and push ‘Start’. You’ll be tracked as if you're doing the actual C2S course - no matter where you are. (*MIA recommend avoiding the middle of the day when the UV rating is higher.)
- When you hit 14kms, the tracking will stop automatically, and your result will be submitted
- Be part of history! All finishers will receive C2S 50 year ‘bling’ (medal) and an exclusive 2020 bandana.
You’re invited to be a Charity Superstar!
Giving back to charity is the beating heart of City2Surf. Melanoma Institute Australia has 20 Charity Superstar places available to our fundraisers. We invite you to become one of 20 MIA Charity Superstars for this year’s City2Surf.
As a Charity Superstar you’ll be part of an exclusive group helping Melanoma Institute Australia achieve our mission of zero deaths from melanoma this decade. You’ll receive the following benefits:
- We’ll cover your C2S entry fee
- You’ll receive a ‘Run over Melanoma’ singlet, MIA hat and SunSense sunscreen
- Be part of the MIA and make a real difference for people impacted by melanoma
- Be rewarded for achieving your fundraising target of $1000 (we’ll support you!)
To apply to become a C2S Charity Superstar please click on the link below:
Together we can run over melanoma!
Visit the City2Surf website for more information about participating in this iconic event.
#City2Surf #LetsRunSydney #RunOverMelanoma.
The Australasian Melanoma Conference is bringing together some of the world's leading researchers and clinicians.
Best practice guidelines for melanoma care have gone digital with the first-ever online guidelines developed to adapt to the rapid change in clinical management.
Congratulations are in order for two of our talented researchers.
Professor Richard Scolyer will be sharing his expertise on melanoma pathology at the upcoming Australasian Melanoma Conference. Here he discusses what he'll be presenting on.
Researchers at MIA have established a High Risk Clinic to monitor people at very high risk of developing melanoma.
A generous donation has enabled a medical oncologist from Portugal to learn from the best in the world at MIA.
MIA is hosting a conference to bring together greats minds in melanoma research that will make a difference to the lives of melanoma patients
Meet Michelle, our Translational Research Officer whose role is to connect the clinics to the lab by ensuring patient blood and tissue samples are documented and carefully stored in our BioSpecimen Bank.
Dr James Wilmott says his Wildfire Award will help expand research into treatment options for people with mucosal melanoma, a rare but deadly form of skin cancer.
Following the recent hype around immunotherapies in cancer, CEO Carole Renouf shares the greatest story never told… resistance… and what MIA is doing to address it.
A/Prof Wargo discusses the research she will be presenting as a keynote speaker at the upcoming Australasian Melanoma Conference.
Dr James Wilmott has been awarded the Wildfire award at this year's Cancer Institute NSW's Premier Awards for Outstanding Cancer Research.
The community has responded generously to our recent appeal to fund a specialised nursing position in an exciting new clinical trial.
We have developed a unique clinical trial that will use existing drugs to target rare genes in melanoma patients.
Data presented at the recent ASCO Annual Meeting showcased advances in melanoma research, particularly long-term survival data.
We value your privacy and want you to be familiar with how we collect, use and disclose your information.
Melanoma Institute Australia has partnered with IBM Research in Australia to help further advance melanoma identification using cognitive technology.
CEO Carole Renouf chats to senior clinicians and researchers as part of our "4 Questions With..." short video series.
MIA's 'Stop the Spread' campaign has been shortlisted in the 2016 Cannes Lions International Festival of Creativity.